Published in J Virol on May 18, 2011
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother (2012) 1.85
Analysis of hepatitis C virus intrahost diversity across the coding region by ultradeep pyrosequencing. J Virol (2012) 1.29
The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A. PLoS Pathog (2013) 1.28
In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother (2012) 1.17
Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother (2012) 1.16
Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep (2014) 1.10
Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling. J Virol (2012) 1.06
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother (2011) 1.05
Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol (2014) 1.04
Involvement of hepatitis C virus NS5A hyperphosphorylation mediated by casein kinase I-α in infectious virus production. J Virol (2014) 1.00
Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol (2013) 0.98
Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity. Antimicrob Agents Chemother (2014) 0.93
Intragenic complementation of hepatitis C virus NS5A RNA replication-defective alleles. J Virol (2012) 0.92
Anti-HCV drugs in the pipeline. Curr Opin Virol (2011) 0.90
Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent. PLoS One (2015) 0.87
Daclatasvir: potential role in hepatitis C. Drug Des Devel Ther (2013) 0.84
Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance. Curr Opin Virol (2014) 0.84
NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes. Antimicrob Agents Chemother (2014) 0.82
Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding. Viruses (2014) 0.82
Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures. PLoS One (2013) 0.81
Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor. Antimicrob Agents Chemother (2011) 0.80
Hepatitis C virus RNA replication depends on specific cis- and trans-acting activities of viral nonstructural proteins. PLoS Pathog (2015) 0.80
Rapid intracellular competition between hepatitis C viral genomes as a result of mitosis. J Virol (2012) 0.79
Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin. Antimicrob Agents Chemother (2014) 0.79
Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems. Antimicrob Agents Chemother (2012) 0.79
The interaction between the hepatitis C proteins NS4B and NS5A is involved in viral replication. Virology (2014) 0.78
A small-molecule inhibitor of hepatitis C virus infectivity. Antimicrob Agents Chemother (2013) 0.78
Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Des Devel Ther (2015) 0.78
A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants. PLoS One (2014) 0.78
Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides. Virology (2014) 0.78
Phosphorylation of Serine 235 of the Hepatitis C Virus Non-Structural Protein NS5A by Multiple Kinases. PLoS One (2016) 0.78
New treatments for chronic hepatitis C: an overview for paediatricians. World J Gastroenterol (2014) 0.77
Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis. Springerplus (2016) 0.75
The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C. J Clin Transl Hepatol (2017) 0.75
Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) (2012) 0.75
Synergistic Activity of Combined NS5A Inhibitors. Antimicrob Agents Chemother (2015) 0.75
Future classes of hepatitis C virus therapeutic agents. Infect Dis Clin North Am (2012) 0.75
Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview. J Clin Transl Hepatol (2016) 0.75
Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 24.31
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Efficient initiation of HCV RNA replication in cell culture. Science (2000) 15.12
The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol (2007) 8.98
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature (2010) 8.95
Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology (2003) 7.35
Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A (2007) 6.79
Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol (2002) 6.69
Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol (2010) 5.87
Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J (1996) 5.47
Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol (2003) 5.41
Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol (1993) 4.57
Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology (1995) 3.87
Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature (2005) 3.83
Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog (2008) 3.81
Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog (2008) 3.77
Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J Virol (1994) 3.51
Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J Virol (1995) 3.41
The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem (2004) 3.15
Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol (2004) 2.97
Quantitative analysis of the hepatitis C virus replication complex. J Virol (2005) 2.91
Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem Biophys Res Commun (1994) 2.89
Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci U S A (2004) 2.77
Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol (2006) 2.77
Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem (2004) 2.71
Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein. J Biol Chem (2005) 2.61
Identification of hepatitis C virus NS5A inhibitors. J Virol (2010) 2.58
Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother (2010) 2.50
Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J Virol (2007) 2.45
euHCVdb: the European hepatitis C virus database. Nucleic Acids Res (2006) 2.41
Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol (2009) 2.39
Topology of the membrane-associated hepatitis C virus protein NS4B. J Virol (2003) 2.37
Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A, and NS4B. J Virol (1999) 2.26
Protein-protein interactions between hepatitis C virus nonstructural proteins. J Virol (2003) 2.23
Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. J Virol (2003) 2.20
Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrob Agents Chemother (2005) 1.94
Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J Biol Chem (2002) 1.75
Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein. J Virol (1999) 1.75
Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication? Virology (2007) 1.74
Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture. J Virol (2004) 1.71
The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus. J Virol (2008) 1.70
A dynamic view of hepatitis C virus replication complexes. J Virol (2008) 1.66
Domain 2 of nonstructural protein 5A (NS5A) of hepatitis C virus is natively unfolded. Biochemistry (2007) 1.53
Efficient rescue of hepatitis C virus RNA replication by trans-complementation with nonstructural protein 5A. J Virol (2005) 1.47
Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α. Gastroenterology (2010) 1.42
Hepatitis C viral life cycle. Adv Drug Deliv Rev (2007) 1.41
Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded. Biochem Biophys Res Commun (2009) 1.34
Hepatitis C treatment: current and future perspectives. Virol J (2010) 1.32
Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon. J Virol (2004) 1.26
Genetic interactions between hepatitis C virus replicons. J Virol (2004) 1.14
New insights into structure and replication of the hepatitis C virus and clinical implications. Semin Liver Dis (2010) 1.13
Replication-competent chimeric hepatitis C virus subgenomic replicons. Intervirology (2005) 1.10
Development of plaque assays for hepatitis C virus-JFH1 strain and isolation of mutants with enhanced cytopathogenicity and replication capacity. Virology (2007) 1.02
Trans-complementation of HCV replication by non-structural protein 5A. Virus Res (2005) 0.99
Mobility analysis of an NS5A-GFP fusion protein in cells actively replicating hepatitis C virus subgenomic RNA. J Gen Virol (2007) 0.99
Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones. Antimicrob Agents Chemother (2005) 0.94
Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture. Bioorg Med Chem Lett (2009) 0.94
Dominant negative effect of wild-type NS5A on NS5A-adapted subgenomic hepatitis C virus RNA replicon. J Gen Virol (2004) 0.89
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature (2010) 8.95
Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science (2003) 7.91
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A (2005) 5.64
Axon regeneration in young adult mice lacking Nogo-A/B. Neuron (2003) 4.23
The mammalian exosome mediates the efficient degradation of mRNAs that contain AU-rich elements. EMBO J (2002) 4.13
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology (2009) 4.00
Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet (2009) 3.59
Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A (2003) 3.38
A role for small RNAs in DNA double-strand break repair. Cell (2012) 3.15
Polymorphisms in interleukin-15 gene on chromosome 4q31.2 are associated with psoriasis vulgaris in Chinese population. J Invest Dermatol (2007) 2.59
Identification of hepatitis C virus NS5A inhibitors. J Virol (2010) 2.58
Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother (2010) 2.50
Activation of the E3 ubiquitin ligase Itch through a phosphorylation-induced conformational change. Proc Natl Acad Sci U S A (2006) 2.49
Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology (2012) 2.29
True versus reported waiting times for valvular aortic stenosis surgery. Can J Cardiol (2006) 2.21
Significant improvement in short-term mortality in women undergoing coronary artery bypass surgery (1991 to 2004). J Am Coll Cardiol (2007) 2.11
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology (2011) 2.10
Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc Natl Acad Sci U S A (2002) 1.96
Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrob Agents Chemother (2005) 1.94
Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model. J Virol (2004) 1.93
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology (2011) 1.83
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology (2005) 1.76
A role for MEK kinase 1 in TGF-beta/activin-induced epithelium movement and embryonic eyelid closure. EMBO J (2003) 1.72
Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol (2003) 1.70
Activation of the interferon-beta promoter during hepatitis C virus RNA replication. Viral Immunol (2002) 1.68
Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol (2008) 1.65
Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production. Nat Immunol (2006) 1.52
Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion? Cardiovasc Pathol (2002) 1.47
Genome-wide association study identifies two new susceptibility loci for atopic dermatitis in the Chinese Han population. Nat Genet (2011) 1.46
Small intestinal hemolymphangioma with bleeding: a case report. World J Gastroenterol (2012) 1.45
Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother (2006) 1.45
Identifying priorities in methodological research using ICD-9-CM and ICD-10 administrative data: report from an international consortium. BMC Health Serv Res (2006) 1.45
Angina with "normal" coronary arteries: sex differences in outcomes. Am Heart J (2007) 1.41
The mortality rate from anorexia nervosa. Int J Eat Disord (2005) 1.40
Trends in wait times for cardiac revascularization. Can J Cardiol (2011) 1.39
Percutaneous coronary intervention and 30-day mortality: the British Columbia PCI risk score. Catheter Cardiovasc Interv (2009) 1.37
Acanthamoeba keratitis: clinical characteristics and management. Ophthalmology (2006) 1.36
Inhibition of hepatitis B virus polymerase by entecavir. J Virol (2007) 1.32
Specific inhibition of bovine viral diarrhea virus replicase. J Virol (2003) 1.28
Fine mapping of the psoriasis susceptibility locus PSORS1 supports HLA-C as the susceptibility gene in the Han Chinese population. PLoS Genet (2008) 1.26
Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology (2013) 1.24
Confirmation by exome sequencing of the pathogenic role of NCSTN mutations in acne inversa (hidradenitis suppurativa). J Invest Dermatol (2011) 1.23
Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. Neoplasia (2012) 1.22
Convergence of Itch-induced ubiquitination with MEKK1-JNK signaling in Th2 tolerance and airway inflammation. J Clin Invest (2006) 1.21
Myosin Va binding to neurofilaments is essential for correct myosin Va distribution and transport and neurofilament density. J Cell Biol (2002) 1.20
Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene (2005) 1.19
Outcome of mitral valve repair or replacement: a comparison by propensity score analysis. Circulation (2003) 1.19
In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother (2012) 1.17
A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog (2010) 1.16
Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis. Nat Genet (2012) 1.12
Human RIF1 encodes an anti-apoptotic factor required for DNA repair. Carcinogenesis (2009) 1.12
Evolution and expression analysis of the grape (Vitis vinifera L.) WRKY gene family. J Exp Bot (2014) 1.11
Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother (2013) 1.11
Do younger women fare worse? Sex differences in acute myocardial infarction hospitalization and early mortality rates over ten years. J Womens Health (Larchmt) (2013) 1.11
Replication-competent chimeric hepatitis C virus subgenomic replicons. Intervirology (2005) 1.10
Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob Agents Chemother (2012) 1.09
The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. J Gen Virol (2011) 1.08
Genetic variation of promoter sequence modulates XBP1 expression and genetic risk for vitiligo. PLoS Genet (2009) 1.07
Downregulation of human farnesoid X receptor by miR-421 promotes proliferation and migration of hepatocellular carcinoma cells. Mol Cancer Res (2012) 1.07
Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother (2012) 1.06
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother (2011) 1.05
Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice. Arthritis Rheum (2010) 1.03
Sex differences in clinical outcomes in patients with stable angina and no obstructive coronary artery disease. Am Heart J (2013) 1.02
Multi-detector CT enterography with iso-osmotic mannitol as oral contrast for detecting small bowel disease. World J Gastroenterol (2005) 1.01
Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors. Antimicrob Agents Chemother (2005) 1.01
A novel linkage to generalized vitiligo on 4q13-q21 identified in a genomewide linkage analysis of Chinese families. Am J Hum Genet (2005) 1.00
Genomic organization, phylogenetic comparison and differential expression of the SBP-box family genes in grape. PLoS One (2013) 1.00
Association analyses identify three susceptibility Loci for vitiligo in the Chinese Han population. J Invest Dermatol (2012) 0.98
Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology (2008) 0.98
Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut (2013) 0.98
Revascularization use and survival outcomes after cardiac catheterization in British Columbia and Alberta. Can J Cardiol (2004) 0.97
Defining NOTCH3 target genes in ovarian cancer. Cancer Res (2012) 0.97
Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm Venereol (2007) 0.96
Sex differences in mortality after transcatheter aortic valve replacement for severe aortic stenosis. J Am Coll Cardiol (2012) 0.96
Genome-wide identification and analysis of the TIFY gene family in grape. PLoS One (2012) 0.95
In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates. J Antimicrob Chemother (2002) 0.95
Characterizations of HCV NS5A replication complex inhibitors. Virology (2013) 0.95
Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease. Digestion (2009) 0.94
Growth and performance of yttrium oxide as an ideal high-kappa gate dielectric for carbon-based electronics. Nano Lett (2010) 0.94
Nogo-C is sufficient to delay nerve regeneration. Mol Cell Neurosci (2003) 0.94
The relationship between XRCC1 and XRCC3 gene polymorphisms and lung cancer risk in northeastern Chinese. PLoS One (2013) 0.93